FDA staff question benefit of AstraZeneca ovarian cancer drug

June 23, 2014 3:11 PM

10 0

FDA staff question benefit of AstraZeneca ovarian cancer drug

(Reuters) - AstraZeneca Plc's experimental ovarian cancer drug, olaparib, showed an 83 percent reduction in the risk of disease progression, but a U.S. Food and Drug Administration staff review has questioned whether the result could be reproduced.

The company's shares fell 1.8 percent to 43.89 pounds on the London Stock Exchange.

Also read: Arkansas conducts nation’s 1st double execution since 2000

Read more

To category page

Loading...